{"corpus_id":16269667,"paper_sha":"19a567459cd617871c2a6e0141e9e475a1c5c3b0","doi":null,"arxiv_id":null,"pmid":22615589,"pmcid":"3232081","mag_id":1500302467,"dblp_id":null,"acl_id":null,"title":"Examination of Setarud (IMOD™) in the management of patients with severe sepsis","year":2010,"publication_date":null,"venue":"DARU","journal":{"name":"DARU : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences","pages":"23 - 28","volume":"18"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article"],"s2_fields_of_study":["Medicine"],"reference_count":20,"citation_count":27,"influential_citation_count":0,"is_open_access":false,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":null,"chemicals":null,"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":null,"s2_open_access_landing_url":null,"s2_open_access_license":null,"s2_open_access_status":null,"pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Background and the purpose of the study Analysis of current immunomodulating strategies indicates that monovalent approaches are unlikely to restore immunostasis or achieve complete therapy of sepsis. Setarud (IMOD) as a mixture of urtica, carotenoids, urea, and selenium has been recently patented for its potential in reduction of Tumor Necrosis Factor alpha (TNF-α) and Interferon-γ and Interleukin-2 levels. The aim of this study was to examine efficacy of IMOD in the management of patients with severe sepsis. Methods Twenty patients with severe sepsis and acute physiology and chronic health evaluation (APACHE) score of more than 20 were randomized to receive standard treatment of severe sepsis (control group) or standard treatment plus IMOD (IMOD group). The group treated with IMOD for 14 days was according to the pilot study and regarding the stability of patient's conditions in the ICU. Of course patients in both groups received standard treatment and all were monitored for 28 days. Blood samples were analyzed for interleukins (IL-1, IL-2, IL-6), plasminogen activator inhibitor (PAI-1), TNF-α, total thiol molecules (TTM), nitric oxide (NO), total antioxidant power (TAP), and lipid peroxidation (LPO). Daily APACHE, Sequential Organ Failure Assessment (SOFA), and Simplified Acute Physiology Score (SAPS) were calculated. Results and major conclusion Comparing with controls, IMOD was significantly effective in improving SAPS, SOFA, and APACHE scores, and reduction of mortality rate. Among tested inflammatory biomarkers, IMOD significantly improved TTM and TNF-α values. It is concluded that IMOD might be added as a safe adjutant to standard treatment of severe sepsis.","claims":[{"public_id":"cl_c5290fca6be96172499cc4fbb63b38a7","status":"active","text":"IMOD added to standard treatment improved SAPS, SOFA, and APACHE scores and reduced mortality in patients with severe sepsis.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_c5290fca6be96172499cc4fbb63b38a7"},{"public_id":"cl_c982ecdaa5707cd19d73e0bee062ace3","status":"active","text":"IMOD might be added as a safe adjunct to standard treatment of severe sepsis.","confidence":0.88,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_c982ecdaa5707cd19d73e0bee062ace3"},{"public_id":"cl_6250938f210f26b25ce69332dc7d204a","status":"active","text":"IMOD significantly improved total thiol molecules and TNF-α among the tested inflammatory biomarkers.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_6250938f210f26b25ce69332dc7d204a"}],"concepts":[{"public_id":"co_0be511c586c99939d2f11e23dcc5dd42","status":"active","name":"total thiol molecules","description":"A measure of circulating thiol-containing antioxidant compounds.","types":["biomarker","antioxidant measure"],"aliases":["TTM"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_0be511c586c99939d2f11e23dcc5dd42"},{"public_id":"co_234a5cae0b85e84e4facfb1ca5cd390d","status":"active","name":"total antioxidant power","description":"An assay of overall antioxidant capacity in blood samples.","types":["biomarker","antioxidant measure"],"aliases":["TAP"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_234a5cae0b85e84e4facfb1ca5cd390d"},{"public_id":"co_6c3f54ce7b55bb63201d66fadad3239a","status":"active","name":"plasminogen activator inhibitor","description":"A blood biomarker involved in regulation of fibrinolysis, measured here as PAI-1.","types":["biomarker"],"aliases":["PAI-1"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_6c3f54ce7b55bb63201d66fadad3239a"},{"public_id":"co_7735b6c8ed28514eb32dc49d001d8b02","status":"active","name":"standard treatment","description":"Routine care provided to patients with severe sepsis in the control and intervention groups.","types":["treatment"],"aliases":["usual care"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_7735b6c8ed28514eb32dc49d001d8b02"},{"public_id":"co_88c2c06200deec4e371fc80a27519b8e","status":"active","name":"APACHE score","description":"A severity-of-illness scoring system used to assess patient acuity.","types":["clinical score"],"aliases":["acute physiology and chronic health evaluation"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_88c2c06200deec4e371fc80a27519b8e"},{"public_id":"co_954dccfab76cdf64890869e2eaad26e2","status":"active","name":"SAPS","description":"The Simplified Acute Physiology Score, a clinical severity score used in critical care.","types":["clinical score"],"aliases":["Simplified Acute Physiology Score"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_954dccfab76cdf64890869e2eaad26e2"},{"public_id":"co_974110895069b7d8f716f1b8d9d2714b","status":"active","name":"interleukins","description":"A group of cytokines measured in blood, including IL-1, IL-2, and IL-6 in this study.","types":["biomarker","cytokine family"],"aliases":["ILs"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_974110895069b7d8f716f1b8d9d2714b"},{"public_id":"co_a958fd99a4f1eee36a54f1f2f5ce1045","status":"active","name":"nitric oxide","description":"A reactive signaling molecule measured as a blood biomarker.","types":["biomarker"],"aliases":["NO"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_a958fd99a4f1eee36a54f1f2f5ce1045"},{"public_id":"co_a9709096343626bac7efbb9fd8f5dd12","status":"active","name":"severe sepsis","description":"A life-threatening systemic response to infection with organ dysfunction, treated here in hospitalized patients.","types":["condition"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_a9709096343626bac7efbb9fd8f5dd12"},{"public_id":"co_ae7e81501a1d5f94a696f2a83ab637ac","status":"active","name":"lipid peroxidation","description":"Oxidative damage to lipids measured as an indicator of oxidative stress.","types":["biomarker","oxidative stress measure"],"aliases":["LPO"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ae7e81501a1d5f94a696f2a83ab637ac"},{"public_id":"co_bccfa47c23ce0058ea2aeb8f67ceed2d","status":"active","name":"Setarud (IMOD™)","description":"A patented immunomodulatory mixture containing urtica, carotenoids, urea, and selenium.","types":["drug","immunomodulator"],"aliases":["IMOD","Setarud"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_bccfa47c23ce0058ea2aeb8f67ceed2d"},{"public_id":"co_e4e309806462a471352e26b36214df16","status":"active","name":"mortality rate","description":"The proportion of patients who died during the 28-day follow-up.","types":["outcome"],"aliases":["death rate"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_e4e309806462a471352e26b36214df16"},{"public_id":"co_e5bd6369dac1a9edf0e6bf9293e801ed","status":"active","name":"TNF-α","description":"Tumor necrosis factor alpha, an inflammatory cytokine measured in blood samples.","types":["biomarker","cytokine"],"aliases":["tumor necrosis factor alpha"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_e5bd6369dac1a9edf0e6bf9293e801ed"},{"public_id":"co_fba70ea6206d5b581b7b895713ffc303","status":"active","name":"SOFA","description":"The Sequential Organ Failure Assessment score used to evaluate organ dysfunction over time.","types":["clinical score"],"aliases":["Sequential Organ Failure Assessment"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_fba70ea6206d5b581b7b895713ffc303"}],"external_ids":{"DOI":null,"ArXiv":null,"PubMed":22615589,"PubMedCentral":"3232081","MAG":1500302467,"DBLP":null,"ACL":null},"open_access":{"is_open_access":false,"pdf_url":null,"landing_url":"https://sah.borca.ai/papers/16269667","source":null,"pdf_url_source":null,"license":null,"reason":"pdf_url_not_indexed"},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":630756,"paper_uid":"c5cd5ebc-00b8-4daa-9b7d-d3bf5e189b5f","canonical_identity":{"paper_id":630756,"paper_uid":"c5cd5ebc-00b8-4daa-9b7d-d3bf5e189b5f","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/16269667"}